Tisdag 19 November | 07:45:36 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-05-06 - Årsstämma
2025-02-12 12:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2024-09-06 13:03:11

Qlife Holding AB (publ) ("Qlife" or the "Company") has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act ("ABL"), prepared a second balance sheet for liquidation purposes, which has been reviewed by the Company's auditor. The balance sheet shows that the Company's total equity exceeds the registered share capital.

On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that the rights issue, approved by the extraordinary general meeting on 16 January 2024, had been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The Company received gross proceeds amounting to approximately MSEK 30.10 from the rights issue, whereby the Company's equity increased by the same amount. Additionally, the Company announced on 8 May 2024, that all outstanding convertible debentures were converted into shares, resulting in an equity increase of approximately MSEK 3.66 in the Company. At the extraordinary general meeting, the first meeting for liquidation purposes, held on 23 April 2024, it was decided that the Company's operations would continue. According to the Swedish Companies Act, the Company is required to hold a second meeting for liquidation purposes within eight months. On 29 August 2024, the Company published the unaudited Q2-report, showing that the Company's equity exceeds the registered share capital. Therefore, the Company prepared a balance sheet for liquidation purposes which now has been reviewed by the Company's auditor. The balance sheet for liquidation purposes shows that the equity exceeds the registered share capital.

The board of directors will call for an extraordinary general meeting, the second meeting for liquidation purposes, where the question of whether the Company should continue its operations or go into liquidation will be reconsidered. Since the second balance sheet shows that the equity in relation to the registered share capital is fully restored, the Company's board of directors will propose continued operations, with liquidation as a secondary option.

"We are happy that the equity is restored and that we can concentrate on what is really important, to move towards commercialization of our product platform, and hence some shareholder value." - Thomas Warthoe, CEO of Qlife Holding AB (publ)

The second balance sheet for liquidation purposes will be available on the Company's website www.qlifeholding.com. It is also attached to this press release in PDF format.

For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34